Roth Capital Upgrades Semtech to Buy, Raises Price Target to $83

Roth Capital analyst Scott Searle upgrades Semtech (NASDAQ:SMTC) from Neutral to Buy and raises the price target from $66 to $83.

byBenzinga Newsdesk

June 3, 2021

1 minute read

Roth Capital analyst Scott Searle upgrades Semtech (NASDAQ:SMTC) from Neutral to Buy and raises the price target from $66 to $83.

‘Jeff Bezos Will Sell Washington Post To Buy Commanders, Investors Say: Sources’ – New York Post

By Benzinga Newsdesk

Today, 12:32 PM

https://nypost.com/2023/01/23/jeff-bezos-will-sell-washington-post-to-buy-commanders-investors/?utm_medium=SocialFlow&utm_source=nypbusinesstwitter&utm_campaign=SocialFlow Does Jeff Bezos love football more than

AMZN

Goldman Sachs Downgrades Ameriprise Financial to Neutral, Lowers Price Target to $270

By Benzinga Newsdesk

Today, 12:32 PM

Goldman Sachs analyst Alexander Blostein downgrades Ameriprise Financial (NYSE:AMP) from Buy to Neutral and lowers the price target from $325 to $270.

AMP

Why Jounce Therapeutics Stock Is Moving Higher Today?

By Vandana Singh

Today, 12:32 PM

The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…

JNCE

FlexShopper Q3 EPS $(0.32) Down From $0.05 YoY, Sales $26.14M Down From $30.86M YoY

By Benzinga Newsdesk

Today, 12:32 PM

FlexShopper (NASDAQ:FPAY) reported quarterly losses of $(0.32) per share. This is a 740 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $26.14 million in sales this

FPAY

Roth Capital Upgrades Semtech to Buy, Raises Price Target to $83

Related Posts

‘Jeff Bezos Will Sell Washington Post To Buy Commanders, Investors Say: Sources’ – New York Post

Goldman Sachs Downgrades Ameriprise Financial to Neutral, Lowers Price Target to $270

Why Jounce Therapeutics Stock Is Moving Higher Today?

FlexShopper Q3 EPS $(0.32) Down From $0.05 YoY, Sales $26.14M Down From $30.86M YoY